Work

Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps9110

Authors: Pasi A. Janne, Helena Alexandra Yu, Melissa Lynne Johnson, Michele Vigliotti, Nicole Shipitofsky, Ferdinand Morales Guevara, Shuquan Chen, Channing Yu

Institutions: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sarah Cannon, Daiichi Sankyo (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891496265

Cites:

Cited by: 4

Related to: 10